Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature.

Babiker A, Clarke L, Doi Y, Shields RK.

Diagn Microbiol Infect Dis. 2019 Nov;95(3):114856. doi: 10.1016/j.diagmicrobio.2019.06.008. Epub 2019 Jun 24.

PMID:
31307867
2.

Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.

Neuner EA, Sekeres J, Hall GS, van Duin D.

Antimicrob Agents Chemother. 2012 Nov;56(11):5744-8. doi: 10.1128/AAC.00402-12. Epub 2012 Aug 27.

3.

Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes.

Giancola SE, Mahoney MV, Hogan MD, Raux BR, McCoy C, Hirsch EB.

Chemotherapy. 2017;62(2):100-104. doi: 10.1159/000449422. Epub 2016 Oct 28.

PMID:
27788499
4.

An update on the management of urinary tract infections in the era of antimicrobial resistance.

Bader MS, Loeb M, Brooks AA.

Postgrad Med. 2017 Mar;129(2):242-258. doi: 10.1080/00325481.2017.1246055. Epub 2016 Oct 21. Review.

PMID:
27712137
5.
6.

Fosfomycin, interesting alternative drug for treatment of urinary tract infections created by multiple drug resistant and extended spectrum β-lactamase producing strains.

Yeganeh-Sefidan F, Ghotaslou R, Akhi MT, Sadeghi MR, Mohammadzadeh-Asl Y, Bannazadeh Baghi H.

Iran J Microbiol. 2016 Apr;8(2):125-31.

7.

Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.

Cho YH, Jung SI, Chung HS, Yu HS, Hwang EC, Kim SO, Kang TW, Kwon DD, Park K.

Int Urol Nephrol. 2015 Jul;47(7):1059-66. doi: 10.1007/s11255-015-1018-9. Epub 2015 May 31.

PMID:
26026972
8.

Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.

Seroy JT, Grim SA, Reid GE, Wellington T, Clark NM.

J Antimicrob Chemother. 2016 Sep;71(9):2563-8. doi: 10.1093/jac/dkw178. Epub 2016 May 30.

PMID:
27246234
9.

Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.

Bader MS, Loeb M, Leto D, Brooks AA.

Postgrad Med. 2019 Oct 24:1-17. doi: 10.1080/00325481.2019.1680052. [Epub ahead of print]

PMID:
31608743
10.

Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer?

Sultan A, Rizvi M, Khan F, Sami H, Shukla I, Khan HM.

Urol Ann. 2015 Jan-Mar;7(1):26-30. doi: 10.4103/0974-7796.148585.

11.

Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.

Veve MP, Wagner JL, Kenney RM, Grunwald JL, Davis SL.

Int J Antimicrob Agents. 2016 Jul;48(1):56-60. doi: 10.1016/j.ijantimicag.2016.04.014. Epub 2016 May 12.

PMID:
27234673
12.

Fosfomycin: In vitro efficacy against multidrug-resistant isolates beyond urinary isolates.

Demir T, Buyukguclu T.

J Glob Antimicrob Resist. 2017 Mar;8:164-168. doi: 10.1016/j.jgar.2016.11.011. Epub 2017 Feb 3.

PMID:
28167307
13.

Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.

Matthews PC, Barrett LK, Warren S, Stoesser N, Snelling M, Scarborough M, Jones N.

BMC Infect Dis. 2016 Oct 11;16(1):556.

14.

Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.

Zykov IN, Samuelsen Ø, Jakobsen L, Småbrekke L, Andersson DI, Sundsfjord A, Frimodt-Møller N.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e02560-17. doi: 10.1128/AAC.02560-17. Print 2018 Jun.

15.

Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens.

Banerjee S, Sengupta M, Sarker TK.

Indian J Urol. 2017 Apr-Jun;33(2):149-154. doi: 10.4103/iju.IJU_285_16.

16.

Fosfomycin Susceptibility in Urinary Tract Enterobacteriaceae.

Patel B, Patel K, Shetty A, Soman R, Rodrigues C.

J Assoc Physicians India. 2017 Sep;65(9):14-16.

PMID:
29313570
17.

Fosfomycin: Mechanism and Resistance.

Silver LL.

Cold Spring Harb Perspect Med. 2017 Feb 1;7(2). pii: a025262. doi: 10.1101/cshperspect.a025262. Review.

18.

In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections.

Gopichand P, Agarwal G, Natarajan M, Mandal J, Deepanjali S, Parameswaran S, Dorairajan LN.

Infect Drug Resist. 2019 Jul 9;12:2005-2013. doi: 10.2147/IDR.S207569. eCollection 2019.

19.

Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012.

Keepers TR, Gomez M, Celeri C, Krause KM, Biek D, Critchley I.

Infect Dis Ther. 2017 Jun;6(2):233-243. doi: 10.1007/s40121-017-0150-5. Epub 2017 Mar 11.

20.

Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.

Patwardhan V, Singh S.

Int Urol Nephrol. 2017 Sep;49(9):1637-1643. doi: 10.1007/s11255-017-1627-6. Epub 2017 Jun 14.

PMID:
28616818

Supplemental Content

Support Center